Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that hepatitis C virus patient opportunity exists within many of the major U.S. local markets: Minneapolis, MN, Boston, MA and Washington DC all have large bases of untreated patients. However, hepatitis C patients often lead high-risk lifestyles and therefore are less likely to carry insurance than the general population.
The new analytics tool entitled PatientFinder: Hepatitis C Virus estimates that while 83.9 percent of the general population has medical insurance, only 67.2 percent of the hepatitis C infected population has coverage. Furthermore, the type of insurance coverage of hepatitis C patients is skewed towards Medicare and Medicaid compared with dominance of private coverage in the general population.
"Biopharmaceutical companies who are targeting hepatitis C patients in the United States need to include these unique insurance dynamics as they prioritize the states and metropolitan statistical areas in which they want to conduct clinical trials, pursue direct-to-consumer advertising and place sales reps," stated Jason LaBonte, Ph.D., vice president of new product development at Decision Resources.
Why Pharmaceutical Companies Need this Information
With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.
PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:
-- Disease-specific prevalence numbers for each U.S. state and MSA -- Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA -- Unique analysis of the untreated population examined through a filter of prescription (Rx) benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory--the true local measure of opportunity for pharmaceutical companies About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 firstname.lastname@example.org email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
firstname.lastname@example.org, or Elizabeth Marshall of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/